home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2806.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
32 lines
Document 2806
DOCN M94A2806
TI Equimmune in treatment of HIV infected patients.
DT 9412
AU Bissbort SH; Davis H; van Brummelen R; Miller S
SO Int Conf AIDS. 1994 Aug 7-12;10(1):220 (abstract no. PB0309). Unique
Identifier : AIDSLINE ICA10/94369769
AB OBJECTIVE: The main objective was to test Equimmune; a recently
formulated immunostimulant, in HIV infected and AIDS patients. METHODS:
An open, multi-center, prospective, clinical trial with 103 patients
with laboratory confirmed HIV positivity and a CD4 count at entry lower
than 650/ml was done. The patients were evaluated at four-weekly
intervals over a 6 month period. The four main variables recorded were
CD4 count, CD4%, S-b2-Microglobulin and Karnofsky score. The change in
variable over time was evaluated statistically by means of the Sign test
and the Wilcoxon Signed Ranks test. RESULTS: A rise in CD4 count (p <
0.0001), as well as in CD4% (p < 0.0001) were observed after already 3
months, this proved to be highly significant. There was an associated
improvement in the Karnofsky score (p < 0.0001), with a significant
decrease in the S-b2-Microglobulin levels (p < 0.0026). No major side
effects were reported. CONCLUSION: Equimmune seems to have a definite
beneficial effect for the HIV infected patient as an immunostimulant.
DE beta 2-Microglobulin/ANALYSIS Acquired Immunodeficiency
Syndrome/THERAPY Adjuvants, Immunologic/*THERAPEUTIC USE Human HIV
Infections/*THERAPY Karnofsky Performance Status Leukocyte Count
Treatment Outcome T4 Lymphocytes CLINICAL TRIAL MEETING ABSTRACT
MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).